CIMIC – Earnings

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter-trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Upcoming key dates
Full year financial results10 February 2022

CIMIC – Buy

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter-trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Bega – Buy

Bega recently provided a trading update, with FY22 underlying EBITDA expected to be in the range of
A$195-215mn.

Earnings have been impacted by supply chain-related disruptions, with some offset by the full-year contribution of the Lion Dairy & Drinks acquisition and related cost synergies. FY23 earnings should reaccelerate and recent shareholder support from Andrew Forrest suggests the current price range is a good opportunity to build a position.

2/2Update: